NASDAQ · SNOA
Healthcare · Drug Manufacturers - Specialty & Generic
$1.11
Down-$0.03 (-2.63%)
Updated Nov 5, 2026, 7:05 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SNOA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
SNOA closed at $1.11 after 21 trading sessions, down 9.02% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.13 | $1.16 | $1.105 | $1.11 | 9.98K |
| Nov 3, 2026 | $1.09 | $1.16 | $1.08 | $1.14 | 36.66K |
| Nov 2, 2026 | $1.08 | $1.1499 | $1.05 | $1.10 | 42.24K |
| Oct 30, 2026 | $1.16 | $1.18 | $1.07 | $1.10 | 85.81K |
| Oct 29, 2026 | $1.1842 | $1.20 | $1.1615 | $1.20 | 20.74K |
| Oct 28, 2026 | $1.14 | $1.20 | $1.1189 | $1.14 | 51.65K |
| Oct 27, 2026 | $1.10 | $1.16 | $1.10 | $1.15 | 33.87K |
| Oct 26, 2026 | $1.12 | $1.20 | $1.10 | $1.12 | 62.8K |
| Oct 23, 2026 | $1.13 | $1.13 | $1.11 | $1.11 | 46.42K |
| Oct 22, 2026 | $1.13 | $1.17 | $1.12 | $1.15 | 16.86K |
| Oct 21, 2026 | $1.17 | $1.19 | $1.12 | $1.14 | 12.84K |
| Oct 20, 2026 | $1.16 | $1.17 | $1.13 | $1.15 | 10.59K |
| Oct 19, 2026 | $1.11 | $1.15 | $1.10 | $1.12 | 42.56K |
| Oct 16, 2026 | $1.2299 | $1.2299 | $1.12 | $1.12 | 57.11K |
| Oct 15, 2026 | $1.15 | $1.21 | $1.12 | $1.15 | 31.3K |
| Oct 14, 2026 | $1.16 | $1.18 | $1.13 | $1.16 | 49.1K |
| Oct 13, 2026 | $1.25 | $1.25 | $1.17 | $1.18 | 47.72K |
| Oct 12, 2026 | $1.24 | $1.29 | $1.22 | $1.23 | 14.88K |
| Oct 9, 2026 | $1.165 | $1.255 | $1.16 | $1.23 | 49.45K |
| Oct 8, 2026 | $1.20 | $1.20 | $1.14 | $1.16 | 89.49K |
| Oct 7, 2026 | $1.23 | $1.23 | $1.20 | $1.22 | 37.85K |
The latest Smart Investors Daily articles mentioning SNOA.
Company
Market Activity
Research & News
SNOA research
Company profile and research snapshot.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 5, 2023 | Ladenburg Thalmann | Buy | — |
| Mar 6, 2018 | Maxim Group | Hold | — |
| Dec 28, 2017 | Benchmark | Speculative Buy | — |
| Nov 10, 2017 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 6, 2026
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.09) per share. This is a 88.16 percent increase over losses of $(0.76) per share from the same period last year. The company reported $6.406 million
Benzinga · Aug 6, 2026
Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.
Benzinga · Jun 30, 2026
Clearance includes expanded claims, clearance for multiple use, and additional packaging configurations.Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare
Benzinga · Jun 18, 2026
- Sec Filing
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNOA.
